Community Oncologists Show Comfort With Bispecifics in B-Cell Lymphoma

EP: 1.Part 1: Treatment Options and Relevant Data for Patients With DLBCL

EP: 2.Part 2: Shah Discusses Challenges in Using Lenalidomide Plus Tafasitamab for Patients With DLBCL

EP: 3.Part 3: Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Promise in Patients With DLBCL

EP: 4.Part 1: Kline Discusses Challenges of CAR T-Cell Therapy in R/R DLBCL

EP: 5.Part 2: Loncastuximab Provides Potential Bridge Therapy for R/R DLBCL

EP: 6.Part 3: Kline Discusses the Use of Tafasitamab in Certain Patients with R/R DLBCL

EP: 7.Part 1: Decision-Making for Third-Line Treatment of Transplant-Ineligible DLBCL

EP: 8.Part 2: Real-World Challenges with CAR T-Cell Therapy in DLBCL

EP: 9.Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL

EP: 10.Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

EP: 11.Part 2: Loncastuximab as a Third-Line Therapy for Relapsed/Refractory DLBCL

EP: 12.Part 3: Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

EP: 13.Part 1: Selecting Third-Line Options for DLBCL With CAR T-Cell Therapy

EP: 14.Part 2: Sequencing Loncastuximab and CAR T-Cell Therapy in DLBCL

EP: 15.Part 1: Tafasitamab/Lenalidomide Shows Durable Responses in R/R DLBCL

EP: 16.Part 2: LOTIS-2 Trial Includes High-Risk Patients and CAR T Sequencing in R/R DLBCL

EP: 17.Part 1: Real-World Barriers to CAR T-Cell Therapy in Advanced DLBCL

EP: 18.Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL

EP: 19.Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCL

EP: 20.Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

EP: 21.Efficacy Data Support Loncastuximab as Third-Line DLBCL Treatment

EP: 22.Physicians Discuss Roles of Later-Line Therapies in DLBCL

EP: 23.Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

EP: 24.Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL

EP: 25.Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL

EP: 26.Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL

EP: 27.Physicians Consider Loncastuximab for Older Patients With R/R DLBCL

EP: 28.Bispecific Agents Vs Loncastuximab as Third-Line Therapy for R/R DLBCL

EP: 29.ADC Loncastuximab Shows Signs of Durable Response in R/R DLBCL

EP: 30.Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

EP: 31.Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

EP: 32.Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

EP: 33.Experience and Sequencing Guide Third-Line DLBCL Therapy Selection

EP: 34.Different Options Discussed for DLBCL in Later-Lines of Treatment

EP: 35.Takeaways on Tolerability Challenges With Loncastuximab in DLBCL

EP: 36.Loncastuximab Leads to Responses in DLBCL After Prior CD19 CAR T

EP: 37.Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL

EP: 38.Later-Line CD19 and Bispecific Therapies Considered After CAR T

Now Viewing

EP: 39.Community Oncologists Show Comfort With Bispecifics in B-Cell Lymphoma

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses the shift she has seen in the community setting when it comes to using bispecific antibody therapy for patients with B-cell lymphoma.

In an interview after a Case-Based Roundtable event she moderated, Brem described how community oncologists are becoming more comfortable using bispecific antibodies for their patients. This change has been assisted by longer availability and the increase in approvals for these drugs in different disease settings, such as lung and skin cancer.

While bispecific antibody therapies were initially used in academic centers, more community practices are adopting these treatments. Large community networks have been able to start using them in practice more quickly and this trend suggests there will be easier access to bispecific therapies in the community setting in the future, according to Brem.

TRANSCRIPTION:

0:10 | One thing that has been really interesting over the last year or 2 is, I think our community partners are getting much more comfortable with bispecific antibodies. I think both as just they have been around longer, and as these things get more approvals and other diseases, right? So, we have multiple agents available lymphomas, multiple agents available in multiple myeloma, but even for many community providers, that is still going to be a very small part of their practice.

0:37 | But now, we are getting them in small cell lung cancer, melanoma, and so I think that as these types of drugs move into the solid tumor space, our community partners are just going to get more and more comfortable with them. Because I think early on, there was a big gap there with bispecifics, where you kind of still had to go to the academic center to get them. I think I am learning that really, over the last 6 months to a year, our community sites, especially the big community networks, are getting on board with them and getting comfortable with them very, very quickly. So, it seems like the access to those drugs is only going to be easier as time goes on.